SURVYR

AQST

Aquestive Therapeutics, Inc.
$4.23
+$0.16 (3.93%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-58%-40%-22%-3%+15%Oct 2025Oct 2026Apr 202652w high $7.1852w low $2.93
AQSTSPY
Wall St. Highest PT $11.00 (+160.0%) Wall St. Avg PT $9.33 (+120.6%)
$3$6$8$11$14POC $4Hi $11Avg $9
Underwater Drawdown %Max DD -57.9%Current -39.6%
0.0%-57.9%
Relative Strength vs SPY-53.5% vs SPYUnderperforming
+69%0%-69%
1W
+$0.18 (4.44%)
1M
−$0.52 (10.95%)
3M
+$0.63 (17.50%)
6M
+$0.18 (4.44%)
YTD
−$2.23 (34.52%)
1Y
−$2.49 (37.05%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
9 analysts · mean score 1.22
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$4.23
Average target$9.33
+$5.10 (+120.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$6.00
Median$9.33
High$11.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-08-24 · HC Wainwright & Co. reiterated Buy on AQST
Reiterated
2025-11-07 · Piper Sandler reiterated Overweight on AQST
Reiterated
2025-10-09 · JMP Securities reiterated Market Outperform on AQST
Reiterated
2025-09-08 · Oppenheimer reiterated Outperform on AQST
Reiterated
2025-06-17 · HC Wainwright & Co. reiterated Buy on AQST
Reiterated
2025-05-15 · HC Wainwright & Co. reiterated Buy on AQST
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$508.3M
P/E (next 12 months, estimated)-7.1
52-week range$2.93 – $7.18
Revenue growth (latest quarter vs a year ago)+38.1%
Dividend yieldNo dividend
Analyst consensusStrong Buy (9)
Average analyst price target$9.33 (+121%)

What they do

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AQST yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AQST earningsNext report in 7 days
Next report
Wed Nov 4, 2026Time not confirmed
EPS consensus-$0.14 range -$0.15–-$0.12
Revenue consensus$11.0M 9 analysts
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.07est -$0.12+45.7%Above estimates
May 13, 2026-$0.05est -$0.13+64.7%Above estimates
Mar 4, 2026-$0.14est -$0.12−18.1%Below estimates
Nov 5, 2025-$0.11est -$0.11−4.2%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 01:31:49 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.220.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$13.8M+38.1%
2026-03-31$14.4M–
2025-12-31$13.0M–
2025-09-30$12.8M–
2025-06-30$10.0M–

News & catalysts

More news
Aquestive Therapeutics Says FDA Accepts Resubmitted Filing for Anaphylm in Severe Allergy
MT Newswires · Oct 15
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
GlobeNewswire · Oct 15
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
MT Newswires · Oct 14
Eton Pharmaceuticals Licenses US Rights to Aquestive's Epilepsy Drug
MT Newswires · Oct 14
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
GlobeNewswire · Oct 14
Rating changes
Reiterated
2026-08-24 · HC Wainwright & Co. reiterated Buy on AQST
Reiterated
2025-11-07 · Piper Sandler reiterated Overweight on AQST
Reiterated
2025-10-09 · JMP Securities reiterated Market Outperform on AQST
Reiterated
2025-09-08 · Oppenheimer reiterated Outperform on AQST
Reiterated
2025-06-17 · HC Wainwright & Co. reiterated Buy on AQST
Reiterated
2025-05-15 · HC Wainwright & Co. reiterated Buy on AQST

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Barber Daniel
Director, President and CEO · 2026-10-15
Sell
$105.6K
Barber Daniel
Director, President and CEO · 2026-09-15
Sell
$120.5K
Korczynski Sherry
Chief Commercial Officer · 2026-09-09
Sell
$45.7K
Barber Daniel
Director, President and CEO · 2026-08-17
Sell
$107.2K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 01:31:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026